Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 7/20 | 0.51 |
| ▸ | NOS3 | P29474 | 5/20 | 0.49 |
| ▸ | NOS2 | P35228 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198725 | 0.78 | HTR5A (0.53) | HTR5ANOS3NOS2TSHRNOS1 | |
| SCHEMBL8736593 | 0.68 | HTR5A (0.50) | HTR5ANOS3NOS2TSHRHDAC8 | |
| SCHEMBL8063228 | 0.66 | NOS3 (1.00) | NOS3NOS2NOS1 | |
| SCHEMBL31703623 | 0.66 | TSHR (0.95) | HTR5ANOS3NOS2TSHR | |
| SCHEMBL1194687 | 0.66 | TSHR (0.95) | HTR5ANOS3NOS2TSHR | |
| Hydrochloric Acid SCHEMBL8090639 | 0.65 | NOS3 (0.97) | NOS3NOS2NOS1 | |
| SCHEMBL8289934 | 0.64 | TSHR (0.38) | HTR5ANOS3NOS2TSHRNOS1 | |
| Hydrochloric Acid SCHEMBL4092945 | 0.64 | TSHR (1.00) | HTR5ANOS3NOS2TSHR | |
| Hydrochloric Acid SCHEMBL29386664 | 0.64 | TSHR (1.00) | HTR5ANOS3NOS2TSHR | |
| SCHEMBL585917 | 0.64 | DRD2 (0.40) | HTR5ANOS3NOS2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| CN-100402499-C | 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2008-07-16 | — | — | CN | disclosed |
| CN-1321996-C | Process for producing 2-iminopyrrolidine derivative | SANITATION STUFF R & D MANAGE (JP) | 2007-06-20 | — | — | CN | disclosed |
| CN-1754880-A | Process for preparing 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-04-05 | — | — | CN | disclosed |
| CN-1243735-C | 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-03-01 | — | — | CN | disclosed |
| CN-1733725-A | Process for preparing 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| CN-1503784-A | 2-iminopyrrolidine derivatives | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | BACE1, BACE2, PSEN1 | HTR5A 1033/4885NOS3 717/4885NOS2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.